>> WELCOME BACK TO CHEDDAR
NEWS, EVERYONE, I'M
KRISTEN SCHOLER LOOK THERE'S A
LOT OF MOVEMENT TODAY REGARDING
THE JOHNSON AND JOHNSON
COVID-19 VACCINES. THE FDA
ORDERING JNJ
TO DISCARD 60 MILLION DOSES OF
ITS COVID VACCINE SHOTS WERE
MADE AT A BALTIMORE PLANT RUN
BY
EMERGENT BIOSOLUTIONS WHICH IS
COME UNDER FIRE AFTER RECEIVING
SEVERAL HEALTH VIOLATIONS
JOINING ME NOW IS JOHN COACH
DEAN OF MIAMI HERBERT BUSINESS
SCHOOL. JOHN THANK YOU SO MUCH
FOR JOINING THIS AFTERNOON.
WHAT DOES THIS MEAN FOR THE
VACCINE ROLLOUT HOW BIG OF A
SETBACK IS IT.
>> I THINK IT'S A SETBACK FOR
JOHNSON
JOHNSON'S REPUTATION OF VERY
FEW PEOPLE WOULD IMAGINE
WOULD BE. SUBCONTRACTING THE
MANUFACTURER OF THE VACCINE.
BUT AS FAR AS THE ROLLOUT IS
CONCERNED. J AND J C SINGLE
DOSE VACCINE WAS REALLY GOING
THE GAME CHANGER AND AS A
RESULT OF
THIS DECISION THERE IS SOME
QUESTION ABOUT WHETHER
THE EXISTING J J VACCINE THAT
IS
GOOD VACCINE. I WILL BE
WELCOMED BY CONSUMERS ALL
WHETHER OR NOT THEY WILL SHY
AWAY FROM THAT. AND SECONDLY
WHETHER OR NOT THERE IS ENOUGH
SUPPLY OF DOSES IN
THE MARKETPLACE TO
ENABLE THE BIDEN GRATION TO
ACHIEVE IT 70% BY JULY 4.
THAT SO THAT'S A QUESTION MARK.
>> LOOK 60 MILLION DOSES OF THE
J AND J VACCINE IS
60 MILLION PEOPLE VACCINATED
FROM THE CORONAVIRUS SINCE IT
IS JUST A SINGLE SHOT.
AND FOR A LOT OF PEOPLE
ESPECIALLY IN RURAL AREAS THEY
WERE RELYING ON THAT SINGLE
DOSE JOHNSON AND JOHNSON
VACCINE WHICH THE BIDEN
ADMINISTRATION HAS
SPOKEN ABOUT I REALLY AS THEIR
MEANS OF ACCESS
TO THIS HOW DOES THIS CHANGE
THE GAME I I UNDERSTAND
OBVIOUSLY THAT THE SHOTS FOR
JOHNSON AND JOHNSON WILL NOT BE
GOING OUT. BUT DOES IT
SIGNIFICANTLY DELAY THE U.S.
FROM REACHING THAT JULY 4TH
GOAL OF HAVING 70% OF THE U.S.
ADULT POPULATION FULLY
VACCINATED.
>> WELL AS I SAID I
THINK IT DOES YEAH SAME TIME
THERE IS NO SHORTAGE OF PFIZER
AND MODERNA ACTUALLY MEANS
AVAILABLE. IT'S JUST THAT
I MORE COMPLEX TO ADMINISTER
BECAUSE THEY REQUIRE 2 DOSES.
ONE THING THAT THE FDA HAS DONE
IS THAT.
>> EXTEND THE SHELF-LIFE THERE
WAS RICE
SHELF LIFE. ALSO J AND J
VACCINE FROM 3 MONTHS TO 4.5
MONTHS.
>> I THINK THIS IS INTENDED AS
A MECHANISM.
>> PROVIDE REASSURANCE TO
>> CLEAR
THE MARKET OF THE DOSES THAT
IT'S ALREADY MANUFACTURED AT
OF COURSE IS MANUFACTURING
ELSEWHERE OUTSIDE OF BALTIMORE
AT A CONSIDERABLE SPEED.
DOSES.
FOR THE U.S. AND OVERSEAS BUT
IT DOES CALL INTO QUESTION THE
70% TO GO.
>> LOOK I GUESS THE QUESTION IS
WHAT DOES IT MEAN FOR J
AND J OUR BIG FOCUS HERE IS ON
CONSUMERS BUT FOR THIS COMPANY
AS WELL IS THERE A
DETRIMENT AGAIN ADD TO ITS
BOTTOM LINE BUT ALSO ITS
REPUTATION IN THE WAKE OF THIS.
>> WELL J J'S S STOCK PRICE HAS
NOT
REALLY MOVED SOME ENORMOUS
COMPANY THIS
IS REALLY ABLETT FROM A REVENUE
AND PROFIT POINT OF VIEW,
HOWEVER, FORMER REP.
>> FACIAL POINT OF AS I AND
I THINK.
>> MOST PEOPLE SIMPLY DO NOT
BELIEVE.
>> J AND
J A CALL OF THE MANUFACTURER OF
WOULD BE SUBCONTRACTING
SOMETHING AS IMPORTANT AS
VACCINE MANUFACTURERS APPLY
THAT ENDS UP THESE VERY
SAFETY AND
PRACTICES SO REPUTATION LEE,
IT'S NOT GOOD FOR
J J. BUT JAY AND JAY HAS A VERY
STRONG BRAND REPUTATION
AND I BELIEVE THAT THEY HAVE
THE ABILITY TO RECOVER CONSUMER
CONFIDENCE.
>> YEAH, I THINK THE STOCK
PRICE DOES TELL A STORY THERE
BUT 60 MILLION DOSES IS STILL
HARD TO WRAP YOUR HEAD AROUND
WHEN WE KNOW THAT MORE PEOPLE
ABSOLUTELY DO NEED
A VACCINE. LET'S SHIFT GEARS
HERE JOHN I WANT TO TALK TALK
ABOUT THE NEWLY APPROVED THE
BIG NEWS THIS WEEK BIOGEN'S ALL
TIMERS DRUG THE FIRST DRUG OF
THIS KIND, IT'S SEEN IN
2 DECADES. A MAJOR PROBLEM
OBVIOUSLY HERE IN THE U.S. IN A
PROBLEM THAT IS EXPECTED
TO WORSEN OVER TIME, BUT IT'S
COME UNDER PROCESS, IT'S COME
UNDER FIRE THERE'S BEEN
CONTROVERSY AROUND THE
APPROVAL. PROCESS WALKING
THROUGH THE ISSUES HERE.
>> WELL THE PRINCIPLE ISSUE
WITH THE SCIENTIFIC ADVISORY
COMMITTEE THE INDEPENDENT
COMMITTEE ADVISING ALL
NOW SIGN-UPS IT CONCLUDED IN
NOVEMBER OF
LAST YEAR. SHOULD NOT BE
APPROVED AT THE EVIDENCE WAS
NOT THERE. AND NEVERTHELESS THE
FDA HAS NOW GO AHEAD AND GIVE
THEM THAT LOST TRACK
OF CREW
WILL NOT DISPROVE BY BEEN ASKED
TO CONDUCT A POSE APPROVAL
STUDY TOOK VALIDATE THE
EFFICACY OF THE DRUG
BUT I THINK WHAT WE'RE SEEING
HERE IS LOOK WE HAVE 6.2
MILLION ALZHEIMER'S PATIENTS IN
THE
UNITED STATES. IT'S A TERRIBLE
DEBILITATING DISEASE.
FAMILIES ARE I'M SURE A
LOT OF STRAIN AND
PRESSURE THE PATIENT ADVOCACY
ASSOCIATION SUCH AS THE OUTSIDE
WAS ASSOCIATION. I HAVE BEEN
PUTTING A LOT OF PRESSURE ON 4
FOR COMMENT FOR THIS DRAW TO
HAVE EMERGENCY APPROVAL.
EVEN THOUGH THE SCIENTISTS TO
REALLY QUESTION MAKING THE
EFFICACY OF THE
DRUG AND AND THANK YOU LOVE THE
EFFORT TO SEE WHEN BALANCE THE
GAINS OF SIDE EFFECTS RELATED
TO BRAIN. SWELLING AND BLAINE
GRAIN, NO BLEEDING.
>> AND WE'VE SEEN MEMBERS OF
THE KEY FDA
ADVISORY PANEL WELL ACTUALLY
RESIGN IN THE WAKE OF THIS
APPROVAL,
SO IT HAS BEEN WRAPPED IN
CONTROVERSY EVEN THOUGH I THINK
FOR MANY FAMILIES MILLIONS OF
FAMILIES. THIS REALLY DID
PROVIDE THEM A LOT OF HOPE THAT
AT LEAST JUST SOME
OF THE ELEMENTS OF THIS COULD
AT LEAST
BE DELAYED. 2 DOWN THE ROAD BUT
I ALSO WANT TO TALK ABOUT THE
PRICE POINT HERE JOHN BECAUSE
THIS IS NOT CHEAP 56,000
DOLLARS
A YEAR TO RECEIVE THIS BIOGEN
TREATMENT FOR ALZHEIMER'S AND
IT'S A LITTLE MORE THAN $4,000
PER INJECTION DO YOU THINK THAT
THAT PRICE IS JUSTIFIED.
>> WELL OVERALL I THINK THAT IS
AN IMPORTANT ISSUE THAT
RELATIVE
TO THE IT'S PROVEN EFFICACY OF
THE TRUCKS ON A
SCIENTIFIC BASIS. ONE MIGHT
QUESTION WHETHER OFF THE THE
$56,000 PRICE POINT ABOUT WHAT
THAT'S NOT ALL. THE HEAT AGAIN
THAT BECAUSE PATIENT IN
QUESTION HAS
MRI EXAMINATIONS DURING THE
COURSE OF THE TREATMENT WHICH
IS AN INFUSION TREATMENT DURING
THE COURSE OF
THE TREATMENT TO CHECK FOR THE
BRAIN SWELLING AND THE GREAT
THINGS. SO THAT'S ADDING
ADDITIONAL COST AND THIS DOES
IT QUESTION MARK OBVIOUSLY THAT
IN A SENSE OF PUBLIC POLICY
DECISION AS TO WHETHER OR
MEDICARE SHOULD
BE PAYING. THIS IS A
MONEY FOR A WHICH HAS NOT COST
MOSCOW WITH THE SCIENTIFIC
ADVISORY BOARD
SUPPOSED TO RECORD THEM BUT TO
WORK TO CALLING
TRUCK SAFETY AND EFFICACY.
>> JOHN I THINK WE'VE GOT TO